Skip to main content
Loading

Elsie Bio

Tuesday, February 27, 2024
Plymouth
CNS/Neurological
Elsie Bio is focused on applying medicinal chemistry to oligonucleotide development. We use DNA encoded technology to design and develop optimal RNA therapeutics. Our approach is redefining how we treat diseases, offering targeted solutions with unprecedented activity and accuracy. With a commitment to groundbreaking science, we're leading the way in developing next-generation RNA therapeutics. Capitalizing on partnerships and data, we intend to develop an unparalleled neurodegenerative pipeline addressing major unmet needs. Our company uses DNA-encoded ultra-high throughput screening to discover optimal sequences and chemical architectures in order to develop therapies with better drug properties. We apply novel chemistry to these optimized molecules that allows access to novel backbones and structures to improve delivery and safety of therapeutics. Our lead assets are in CNS with a focus on treating neurodegenerative diseases in a non-invasive, cell-specific manner.
Speakers
Kevin Green, COO - Elsie Bio

State

CA

Country

United States

Website

http://www.elsiebio.com

CEO/Top Company Official

Kevin Green

Lead Product in Development

antisense treating Parkinson's disease

Development Phase of Primary Product

Pre-Clinical
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Media Partner


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP